Azacitidine in AML/MDS after allogeneic HSCT. 台北榮總血液腫瘤科 楊元豪 / 高志平大夫. Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Azacitidine in AML/MDS after allogeneic HSCT
-Silverman LR, et al., JCO 2002
Time to leukemia transformation
-Platzbecker U, et al., Leukemia 2012